<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03965052</url>
  </required_header>
  <id_info>
    <org_study_id>SOPH179-0818/I</org_study_id>
    <nct_id>NCT03965052</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan®</brief_title>
  <acronym>PRO-179/I</acronym>
  <official_title>Phase I Clinical Study, to Evaluate the Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan®, on the Ocular Surface of Clinically Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Sophia S.A de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Sophia S.A de C.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I clinical study, to evaluate the safety and tolerability of the ophthalmic solution
      PRO-179 compared with Travatan®, on the ocular surface of clinically healthy subjects.

      Goals: To evaluate the safety and tolerability of the formulation PRO-179 manufactured by
      Sophia Laboratories S.A. of C.V. on the ocular surface of clinically healthy subjects.

      Hypothesis:The ophthalmic solution PRO-179 presents a profile of safety and tolerability
      similar to Travatan® in healthy subjects.

      Methodology: Clinical trial Phase I, controlled, of parallel groups, double blind, with
      randomization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Number of patients: n= 24, 12 subjects per group (both eyes). Main inclusion criteria:
      Clinically healthy subjects.

      duration: 10 days.

      Duration of subject in the study: 15 to 22 days.

      Adverse events will be reported and cataloged based on the MedDRA dictionary and will be
      reported to the corresponding regulatory entity.

      The sponsor will carry out monitoring or quality visits to the research sites where it
      corroborates the information of the source documents and will contrast them with the
      information presented in the electronic CRF. Electronic case report forms will be evaluated
      by the clinical research associate and the clinical team of the sponsor (medical
      ophthalmologist researcher and pharmacologist of clinical safety).

      Statistical methodology:

      The data will be expressed with measures of central tendency: mean and standard deviation for
      the quantitative variables. The qualitative variables will be presented in frequencies and
      percentages. The statistical analysis will be carried out by means of the Mann-Whitney U test
      for the quantitative variables for the difference between the groups. The difference between
      the qualitative variables will be analyzed by means of X2 (Chi2) or Fisher's exact. An alpha
      ≤ 0.05 will be considered significant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 24, 2019</start_date>
  <completion_date type="Actual">August 29, 2019</completion_date>
  <primary_completion_date type="Actual">July 2, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double blind, with randomization.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Blinding will correspond to the principal investigator and coinvestigator. In addition, the statistical analysis will be carried out in a blinded manner for the final analysis. Blinding can not be guaranteed in the subject.
The masking will be done through the secondary container. The primary packaging will not be masked by the morphological difference between them. The sponsor and the research center will have two teams blinded / not blinded.
They will be identified by means of identical labels. Which, in accordance with current and applicable regulations, must contain at least:
Name, address and telephone number of the sponsor.
Pharmaceutical form and route of administration.
Lot Number.
Legend &quot;Exclusively for clinical studies&quot;
Date of Expiry.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>during the 14 days of evaluation, including the safety call (day 14).</time_frame>
    <description>primary security variable the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent. it will be evaluated by the number of reported cases per group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Eye Comfort Index</measure>
    <time_frame>will be evaluated at the end of the treatment, at the final visit (day 11)</time_frame>
    <description>It is a questionnaire designed to measure the irritation of the ocular surface with Rasch analysis to produce estimates on a linear scale of intervals (ratings: 0-100).The Eye comfort index contains items that focus on the discomfort associated with alterations of the ocular surface.(0: None discomfort, 100: high discomfort).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes With Epithelial Defects by Grade</measure>
    <time_frame>will be evaluated at the end of the treatment, at the final visit (day 11)</time_frame>
    <description>The epithelial defects will be evaluated by means of two stains, lissamine green and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Ability</measure>
    <time_frame>will be evaluated at the end of the treatment, at the final visit (day 11)</time_frame>
    <description>The visual capacity variable will be reported using as a unit of measure a fraction, this is taken from a visual test with the Snellen primer, it is a Nominal type variable. where the optimal vision is 20/20 and the worst vision is 20/200, higher values represent a worst vision. The result of the Snellen chart has equivalents in an international logarithmic system called Logmar (logarithm of the minimum angle of resolution) for better understanding.
Snellen Scale: 20/200, 20/100, 20/50, 20/40, 20/30, 20/25, 20/20, 20/15, 20/12, 20/10.
Snellen / LogMAR equivalences: 20/200= 1.0, 20/100=0.7, 20/50=0.4, 20/40=0.3, 20/30=0.2, 20/25=0.1, 20/20=0.0, 20/15=0.13, 20/12=0.2, 20/10=-0.3, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Eyes With Conjunctival Hyperemia (CH) by Grade</measure>
    <time_frame>will be evaluated at the end of the treatment, at the final visit (day 11)</time_frame>
    <description>Conjunctival hyperemia will be evaluated as an ordinal variable, by direct observation and staged using the Efron scale as Normal / Very Light / Mild / Moderate / Severe. Based on this scale, the normal and mild stages are considered without pathologies or normal. Mild, moderate and severe are considered pathological.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes of Chemosis</measure>
    <time_frame>will be evaluated at the end of the treatment, at the final visit (day 11)</time_frame>
    <description>The chemosis will be evaluated, as a nominal variable, by direct observation and it will be staged as present and absent, where the normality is that said variable is absent.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in Intraocular Pressure</measure>
    <time_frame>will be evaluated at the end of the treatment, at the final visit (day 11)</time_frame>
    <description>the intraocular pressure will be evaluated by means of the Goldman applanation tonometry whose unit of measurement is millimeters of mercury (mmHg), it is a continuous variable and its normality range is between 11 - 21 mmHg</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>PRO-179</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage: 1 drop every 24 hours, at night, in both eyes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Travatan®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dosage: 1 drop every 24 hours, at night, in both eyes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO 179</intervention_name>
    <description>Generic name: Travoprost
Distinctive denomination: Bristrio® (PRO-179)
Active principles: Travoprost 0.004%.
Pharmaceutical form: Ophthalmic solution
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Sophia Laboratories, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene.</description>
    <arm_group_label>PRO-179</arm_group_label>
    <other_name>PRO-179</other_name>
    <other_name>Bristrio®</other_name>
    <other_name>Travoprost 0.004% ophthalmic solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travatan 0.004 % Ophthalmic Solution</intervention_name>
    <description>Generic name: Travoprost
Distinctive denomination: Travatan®
Active ingredients: Travoprost 0.004%
Pharmaceutical form: Ophthalmic solution.
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Alcon Laboratories Inc.
Description of the solution: transparent solution, free of visible particles.
Consult information to prescribe.</description>
    <arm_group_label>Travatan®</arm_group_label>
    <other_name>Travoprost 0.004% ophthalmic solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be clinically healthy.

          -  Have the ability to give their signed informed consent and show willingness to comply
             with the study procedures

          -  Have an age between 18 to 45 years.

          -  Indistinct sex.

          -  Women should ensure the continued use of a hormonal contraceptive method or
             intrauterine device (IUD) during the study period.

          -  Present blood tests: within normal parameters or with a range of ± 20% as long as the
             subject is clinically healthy.

        Blood count (BH): Hemoglobin, erythrocytes, hematocrit, total leukocytes, platelets, mean
        corpuscular volume and mean corpuscular hemoglobin.

          -  Blood chemistry of three elements (QS): Glucose, urea and creatinine.

          -  Liver function tests (PFH): Aspartate Aminotransferase and Alanine Aminotransferase,
             total bilirubin, direct and indirect.

               -  Present visual ability 20/30 or better in both eyes.

               -  Present vital signs within normal parameters.

               -  Present intraocular pressure ≥10 and ≤ 21 mmHg.

        Exclusion Criteria:

          -  Be a user of topical ophthalmic products of any kind.

          -  Be a user of medicines, or herbal products, by any other route of administration, with
             the exception of hormonal contraceptives in the case of women.

          -  In case of being a woman, being pregnant or breastfeeding.

          -  Have participated in clinical research studies 90 days prior to inclusion in the
             present study.

          -  Have previously participated in this same study.

          -  Be a user of contact lenses and can not suspend their use during the study.

          -  That they can not follow the lifestyle considerations described in section 6.2.2

          -  Having started the use of hormonal contraceptives or IUD, 30 days prior to inclusion
             in the present study.

          -  Having a history of any chronic-degenerative disease.

          -  Present inflammatory or infectious disease, active at the time of admission to the
             study.

          -  Present injuries or unresolved traumas at the time of entering the study.

          -  Having the antecedent of any type of eye surgery.

          -  Having undergone surgical procedures, not ophthalmological, in the last 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leopoldo Baiza Durán, MD</last_name>
    <role>Study Director</role>
    <affiliation>Laboratorios Sophia S.A de C.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jose Navarro Partida</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>45160</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <results_first_submitted>November 4, 2019</results_first_submitted>
  <results_first_submitted_qc>November 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 12, 2019</results_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Travoprost</keyword>
  <keyword>ophthalmic solution</keyword>
  <keyword>Prostaglandin Analogues</keyword>
  <keyword>Antiglaucoma drugs</keyword>
  <keyword>glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Travoprost</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT03965052/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PRO-179</title>
          <description>Dosage: 1 drop every 24 hours, at night, in both eyes.
PRO 179: o Generic name: Travoprost
Distinctive denomination: Bristrio® (PRO-179)
Active principles: Travoprost 0.004%.
Pharmaceutical form: Ophthalmic solution
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Sophia Laboratories, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene.</description>
        </group>
        <group group_id="P2">
          <title>Travatan®</title>
          <description>Dosage: 1 drop every 24 hours, at night, in both eyes.
Travatan 0.004 % Ophthalmic Solution: o Generic name: Travoprost
Distinctive denomination: Travatan®
Active ingredients: Travoprost 0.004%
Pharmaceutical form: Ophthalmic solution.
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Alcon Laboratories Inc.
Description of the solution: transparent solution, free of visible particles.
Consult information to prescribe.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PRO-179</title>
          <description>Dosage: 1 drop every 24 hours, at night, in both eyes.
PRO 179: o Generic name: Travoprost
Distinctive denomination: Bristrio® (PRO-179)
Active principles: Travoprost 0.004%.
Pharmaceutical form: Ophthalmic solution
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Sophia Laboratories, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene.</description>
        </group>
        <group group_id="B2">
          <title>Travatan®</title>
          <description>Dosage: 1 drop every 24 hours, at night, in both eyes.
Travatan 0.004 % Ophthalmic Solution: o Generic name: Travoprost
Distinctive denomination: Travatan®
Active ingredients: Travoprost 0.004%
Pharmaceutical form: Ophthalmic solution.
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Alcon Laboratories Inc.
Description of the solution: transparent solution, free of visible particles.
Consult information to prescribe.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.2" spread="8.0"/>
                    <measurement group_id="B2" value="24.7" spread="4.6"/>
                    <measurement group_id="B3" value="26.3" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Latin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>primary security variable the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent. it will be evaluated by the number of reported cases per group.</description>
        <time_frame>during the 14 days of evaluation, including the safety call (day 14).</time_frame>
        <population>the analysis was carried out by intention to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-179</title>
            <description>Dosage: 1 drop every 24 hours, at night, in both eyes.
PRO 179: o Generic name: Travoprost
Distinctive denomination: Bristrio® (PRO-179)
Active principles: Travoprost 0.004%.
Pharmaceutical form: Ophthalmic solution
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Sophia Laboratories, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene.</description>
          </group>
          <group group_id="O2">
            <title>Travatan®</title>
            <description>Dosage: 1 drop every 24 hours, at night, in both eyes.
Travatan 0.004 % Ophthalmic Solution: o Generic name: Travoprost
Distinctive denomination: Travatan®
Active ingredients: Travoprost 0.004%
Pharmaceutical form: Ophthalmic solution.
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Alcon Laboratories Inc.
Description of the solution: transparent solution, free of visible particles.
Consult information to prescribe.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>primary security variable the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent. it will be evaluated by the number of reported cases per group.</description>
          <population>the analysis was carried out by intention to treat (ITT)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Eye Comfort Index</title>
        <description>It is a questionnaire designed to measure the irritation of the ocular surface with Rasch analysis to produce estimates on a linear scale of intervals (ratings: 0-100).The Eye comfort index contains items that focus on the discomfort associated with alterations of the ocular surface.(0: None discomfort, 100: high discomfort).</description>
        <time_frame>will be evaluated at the end of the treatment, at the final visit (day 11)</time_frame>
        <population>the analysis was per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-179</title>
            <description>Dosage: 1 drop every 24 hours, at night, in both eyes.
PRO 179: o Generic name: Travoprost
Distinctive denomination: Bristrio® (PRO-179)
Active principles: Travoprost 0.004%.
Pharmaceutical form: Ophthalmic solution
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Sophia Laboratories, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene.</description>
          </group>
          <group group_id="O2">
            <title>Travatan®</title>
            <description>Dosage: 1 drop every 24 hours, at night, in both eyes.
Travatan 0.004 % Ophthalmic Solution: o Generic name: Travoprost
Distinctive denomination: Travatan®
Active ingredients: Travoprost 0.004%
Pharmaceutical form: Ophthalmic solution.
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Alcon Laboratories Inc.
Description of the solution: transparent solution, free of visible particles.
Consult information to prescribe.</description>
          </group>
        </group_list>
        <measure>
          <title>Eye Comfort Index</title>
          <description>It is a questionnaire designed to measure the irritation of the ocular surface with Rasch analysis to produce estimates on a linear scale of intervals (ratings: 0-100).The Eye comfort index contains items that focus on the discomfort associated with alterations of the ocular surface.(0: None discomfort, 100: high discomfort).</description>
          <population>the analysis was per protocol</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.61" spread="11.3"/>
                    <measurement group_id="O2" value="28.97" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes With Epithelial Defects by Grade</title>
        <description>The epithelial defects will be evaluated by means of two stains, lissamine green and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.</description>
        <time_frame>will be evaluated at the end of the treatment, at the final visit (day 11)</time_frame>
        <population>The analysis was per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-179</title>
            <description>Dosage: 1 drop every 24 hours, at night, in both eyes.
PRO 179: o Generic name: Travoprost
Distinctive denomination: Bristrio® (PRO-179)
Active principles: Travoprost 0.004%.
Pharmaceutical form: Ophthalmic solution
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Sophia Laboratories, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene.</description>
          </group>
          <group group_id="O2">
            <title>Travatan®</title>
            <description>Dosage: 1 drop every 24 hours, at night, in both eyes.
Travatan 0.004 % Ophthalmic Solution: o Generic name: Travoprost
Distinctive denomination: Travatan®
Active ingredients: Travoprost 0.004%
Pharmaceutical form: Ophthalmic solution.
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Alcon Laboratories Inc.
Description of the solution: transparent solution, free of visible particles.
Consult information to prescribe.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With Epithelial Defects by Grade</title>
          <description>The epithelial defects will be evaluated by means of two stains, lissamine green and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.</description>
          <population>The analysis was per protocol</population>
          <units>eyes</units>
          <param>Count of Units</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Green lissamine grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Green lissamine grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Green lissamine grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Green lissamine grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Green lissamine grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fluorescein grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fluorescein grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fluorescein grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fluorescein grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fluorescein grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lissamine green treatment groups</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fluorescein treatment groups</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.667</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Ability</title>
        <description>The visual capacity variable will be reported using as a unit of measure a fraction, this is taken from a visual test with the Snellen primer, it is a Nominal type variable. where the optimal vision is 20/20 and the worst vision is 20/200, higher values represent a worst vision. The result of the Snellen chart has equivalents in an international logarithmic system called Logmar (logarithm of the minimum angle of resolution) for better understanding.
Snellen Scale: 20/200, 20/100, 20/50, 20/40, 20/30, 20/25, 20/20, 20/15, 20/12, 20/10.
Snellen / LogMAR equivalences: 20/200= 1.0, 20/100=0.7, 20/50=0.4, 20/40=0.3, 20/30=0.2, 20/25=0.1, 20/20=0.0, 20/15=0.13, 20/12=0.2, 20/10=-0.3, etc.</description>
        <time_frame>will be evaluated at the end of the treatment, at the final visit (day 11)</time_frame>
        <population>the analysis was per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-179</title>
            <description>Dosage: 1 drop every 24 hours, at night, in both eyes.
PRO 179: o Generic name: Travoprost
Distinctive denomination: Bristrio® (PRO-179)
Active principles: Travoprost 0.004%.
Pharmaceutical form: Ophthalmic solution
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Sophia Laboratories, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene.</description>
          </group>
          <group group_id="O2">
            <title>Travatan®</title>
            <description>Dosage: 1 drop every 24 hours, at night, in both eyes.
Travatan 0.004 % Ophthalmic Solution: o Generic name: Travoprost
Distinctive denomination: Travatan®
Active ingredients: Travoprost 0.004%
Pharmaceutical form: Ophthalmic solution.
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Alcon Laboratories Inc.
Description of the solution: transparent solution, free of visible particles.
Consult information to prescribe.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Ability</title>
          <description>The visual capacity variable will be reported using as a unit of measure a fraction, this is taken from a visual test with the Snellen primer, it is a Nominal type variable. where the optimal vision is 20/20 and the worst vision is 20/200, higher values represent a worst vision. The result of the Snellen chart has equivalents in an international logarithmic system called Logmar (logarithm of the minimum angle of resolution) for better understanding.
Snellen Scale: 20/200, 20/100, 20/50, 20/40, 20/30, 20/25, 20/20, 20/15, 20/12, 20/10.
Snellen / LogMAR equivalences: 20/200= 1.0, 20/100=0.7, 20/50=0.4, 20/40=0.3, 20/30=0.2, 20/25=0.1, 20/20=0.0, 20/15=0.13, 20/12=0.2, 20/10=-0.3, etc.</description>
          <population>the analysis was per protocol</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0"/>
                    <measurement group_id="O2" value="0.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Eyes With Conjunctival Hyperemia (CH) by Grade</title>
        <description>Conjunctival hyperemia will be evaluated as an ordinal variable, by direct observation and staged using the Efron scale as Normal / Very Light / Mild / Moderate / Severe. Based on this scale, the normal and mild stages are considered without pathologies or normal. Mild, moderate and severe are considered pathological.</description>
        <time_frame>will be evaluated at the end of the treatment, at the final visit (day 11)</time_frame>
        <population>the analysis was per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-179</title>
            <description>Dosage: 1 drop every 24 hours, at night, in both eyes.
PRO 179: o Generic name: Travoprost
Distinctive denomination: Bristrio® (PRO-179)
Active principles: Travoprost 0.004%.
Pharmaceutical form: Ophthalmic solution
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Sophia Laboratories, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene.</description>
          </group>
          <group group_id="O2">
            <title>Travatan®</title>
            <description>Dosage: 1 drop every 24 hours, at night, in both eyes.
Travatan 0.004 % Ophthalmic Solution: o Generic name: Travoprost
Distinctive denomination: Travatan®
Active ingredients: Travoprost 0.004%
Pharmaceutical form: Ophthalmic solution.
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Alcon Laboratories Inc.
Description of the solution: transparent solution, free of visible particles.
Consult information to prescribe.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With Conjunctival Hyperemia (CH) by Grade</title>
          <description>Conjunctival hyperemia will be evaluated as an ordinal variable, by direct observation and staged using the Efron scale as Normal / Very Light / Mild / Moderate / Severe. Based on this scale, the normal and mild stages are considered without pathologies or normal. Mild, moderate and severe are considered pathological.</description>
          <population>the analysis was per protocol</population>
          <units>eyes</units>
          <param>Count of Units</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very mild (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>the analysis was per protocol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.977</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes of Chemosis</title>
        <description>The chemosis will be evaluated, as a nominal variable, by direct observation and it will be staged as present and absent, where the normality is that said variable is absent.</description>
        <time_frame>will be evaluated at the end of the treatment, at the final visit (day 11)</time_frame>
        <population>the analysis was per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-179</title>
            <description>Dosage: 1 drop every 24 hours, at night, in both eyes.
PRO 179: o Generic name: Travoprost
Distinctive denomination: Bristrio® (PRO-179)
Active principles: Travoprost 0.004%.
Pharmaceutical form: Ophthalmic solution
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Sophia Laboratories, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene.</description>
          </group>
          <group group_id="O2">
            <title>Travatan®</title>
            <description>Dosage: 1 drop every 24 hours, at night, in both eyes.
Travatan 0.004 % Ophthalmic Solution: o Generic name: Travoprost
Distinctive denomination: Travatan®
Active ingredients: Travoprost 0.004%
Pharmaceutical form: Ophthalmic solution.
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Alcon Laboratories Inc.
Description of the solution: transparent solution, free of visible particles.
Consult information to prescribe.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes of Chemosis</title>
          <description>The chemosis will be evaluated, as a nominal variable, by direct observation and it will be staged as present and absent, where the normality is that said variable is absent.</description>
          <population>the analysis was per protocol</population>
          <units>eyes</units>
          <param>Count of Units</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in Intraocular Pressure</title>
        <description>the intraocular pressure will be evaluated by means of the Goldman applanation tonometry whose unit of measurement is millimeters of mercury (mmHg), it is a continuous variable and its normality range is between 11 - 21 mmHg</description>
        <time_frame>will be evaluated at the end of the treatment, at the final visit (day 11)</time_frame>
        <population>the analysis was per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-179</title>
            <description>Dosage: 1 drop every 24 hours, at night, in both eyes.
PRO 179: o Generic name: Travoprost
Distinctive denomination: Bristrio® (PRO-179)
Active principles: Travoprost 0.004%.
Pharmaceutical form: Ophthalmic solution
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Sophia Laboratories, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene.</description>
          </group>
          <group group_id="O2">
            <title>Travatan®</title>
            <description>Dosage: 1 drop every 24 hours, at night, in both eyes.
Travatan 0.004 % Ophthalmic Solution: o Generic name: Travoprost
Distinctive denomination: Travatan®
Active ingredients: Travoprost 0.004%
Pharmaceutical form: Ophthalmic solution.
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Alcon Laboratories Inc.
Description of the solution: transparent solution, free of visible particles.
Consult information to prescribe.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Intraocular Pressure</title>
          <description>the intraocular pressure will be evaluated by means of the Goldman applanation tonometry whose unit of measurement is millimeters of mercury (mmHg), it is a continuous variable and its normality range is between 11 - 21 mmHg</description>
          <population>the analysis was per protocol</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.95" spread="1.6"/>
                    <measurement group_id="O2" value="10.71" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were evaluated for about 2 months and one week until the last follow-up call of the last subject.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PRO-179</title>
          <description>Dosage: 1 drop every 24 hours, at night, in both eyes.
PRO 179: o Generic name: Travoprost
Distinctive denomination: Bristrio® (PRO-179)
Active principles: Travoprost 0.004%.
Pharmaceutical form: Ophthalmic solution
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Sophia Laboratories, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene.</description>
        </group>
        <group group_id="E2">
          <title>Travatan®</title>
          <description>Dosage: 1 drop every 24 hours, at night, in both eyes.
Travatan 0.004 % Ophthalmic Solution: o Generic name: Travoprost
Distinctive denomination: Travatan®
Active ingredients: Travoprost 0.004%
Pharmaceutical form: Ophthalmic solution.
Presentation: multi-dose dropper bottle, 2.5 milliliters.
Prepared by: Alcon Laboratories Inc.
Description of the solution: transparent solution, free of visible particles.
Consult information to prescribe.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>ocular hypotony</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>ocular burning</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>eye pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>eyelid pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>photophobia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>ocular hypotony</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>eyelid swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>tearing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>red eye</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>eye itching</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>foreign body sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Principal Investigator undertakes not to publish or communicate data collected from the study, unless there is prior written agreement of Laboratorios Sophia, S.A. from C.V.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>PhD. Ricardo Llamas</name_or_title>
      <organization>Laboratorios Sophia</organization>
      <phone>+52 (33) 3001 4200 ext 1259</phone>
      <email>ricardo.llamas@sophia.com.mx</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

